Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 120.16M P/E - EPS this Y 37.40% Ern Qtrly Grth -
Income -227.28M Forward P/E -0.64 EPS next Y 14.70% 50D Avg Chg -26.00%
Sales 68.62M PEG -0.13 EPS past 5Y - 200D Avg Chg -51.00%
Dividend N/A Price/Book 3.20 EPS next 5Y 15.80% 52W High Chg -86.00%
Recommedations 1.80 Quick Ratio 4.09 Shares Outstanding 96.23M 52W Low Chg 22.00%
Insider Own 20.80% ROA -24.08% Shares Float 65.55M Beta 1.70
Inst Own 40.52% ROE - Shares Shorted/Prior 1M/888.13K Price 1.49
Gross Margin -86.89% Profit Margin - Avg. Volume 519,106 Target Price 10.00
Oper. Margin -186.19% Earnings Date Aug 6 Volume 339,555 Change -1.32%
About ADC Therapeutics SA

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics SA News
05/15/24 ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
05/10/24 ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations
05/09/24 Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
05/09/24 ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
05/09/24 ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
05/07/24 ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
05/06/24 ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
05/06/24 ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
05/06/24 ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial
05/06/24 ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
05/06/24 ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
05/01/24 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
05/01/24 ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
04/04/24 ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
04/03/24 ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
03/16/24 US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
03/15/24 ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
03/14/24 Q4 2023 ADC Therapeutics SA Earnings Call
03/13/24 ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset
03/13/24 ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADCT Chatroom

User Image Americanbulls Posted - 3 days ago

$ADCT the bull pattern is not confirmed. A new bull pattern is detected. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=ADCT

User Image Spartrap Posted - 4 days ago

$ADCT we'll probably get an ASCO abstracts PR today.. I can find 2 of them, a poster on Lotis-5 and another about Quantitative Systems Pharmacology whatever that is

User Image tkrevver Posted - 5 days ago

$ADCT Welp, it really did try to hold the trend line for days and weeks, but finally broke through the wedge on the downside :( Still long and strong, but definitely iffy in the short-term until the next catalyst. Probably too many profit-takers for now. Daily chart.

User Image fmalad Posted - 6 days ago

$ADCT buying opportunity!

User Image Pharmer23 Posted - 6 days ago

$ADCT doesn’t redmile already own a ton of shares . So they participated major in the last offering .. https://m.ca.investing.com/news/company-news/redmile-group-acquires-691-million-in-adc-therapeutics-prefunded-warrants-93CH-3402516?ampMode=1

User Image popculture Posted - 6 days ago

$ADCT man can this see sub 1 again before 5 bucks ?

User Image alikp76 Posted - 6 days ago

$ADCT how painful to observe it after big way up, no news no movement up

User Image Pharmer23 Posted - 1 week ago

$ADCT I firmly believe patience will pay here .

User Image HotOnessssss Posted - 1 week ago

$ADCT

User Image HotOnessssss Posted - 1 week ago

$ADCT

User Image Americanbulls Posted - 1 week ago

$ADCT may go up 43% if the bull pattern is confirmed. Check confirmation [36%] @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=ADCT. Buy level:4.14.

User Image HotOnessssss Posted - 1 week ago

$ADCT $10.00 stock in 3 months.

User Image HotOnessssss Posted - 1 week ago

$ADCT ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ GLOBENEWSWIRE 7:15 AM ET 5/15/2024

User Image HotOnessssss Posted - 1 week ago

$ADCT

User Image fmalad Posted - 1 week ago

$ADCT loaded up today at 3.89 . Thank you shorts!

User Image Doggo2010 Posted - 1 week ago

$ADCT 8-k is the investor presentation. https://www.sec.gov/Archives/edgar/data/1771910/000095010324006646/dp211180_ex9901.htm

User Image Pharmer23 Posted - 1 week ago

$ADCT they done fuckin with this ??? Jeeezzzz imma bout to get palpitations lol

User Image HotOnessssss Posted - 2 weeks ago

$ADCT 8-K out

User Image Pharmer23 Posted - 2 weeks ago

$ADCT this is brutal .

User Image Pharmer23 Posted - 2 weeks ago

$ADCT if I wasn’t so balls deep in this I would be adding hand over fist

User Image Pharmer23 Posted - 2 weeks ago

$ADCT ~15% under offering price . Madness

User Image HotOnessssss Posted - 2 weeks ago

$ADCT Absolutely no reason for this dip. Added another 1,000 shares at 4.36

User Image Spartrap Posted - 2 weeks ago

$ADCT $339M in cash. Trading at an offering-adjusted $435M MC

User Image ButterCapital Posted - 2 weeks ago

$ADCT 🤓

User Image Spartrap Posted - 2 weeks ago

$ADCT this beta is giving me motion sickness fr

User Image Spartrap Posted - 2 weeks ago

$ADCT ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.

User Image HotOnessssss Posted - 2 weeks ago

$ADCT offering closed - only up from here!!!

User Image HotOnessssss Posted - 2 weeks ago

$ADCT OFFERING CLOSED: The Shares were offered to investors at $4.900 per Share and the Pre-Funded Warrants were offered to investors at $4.812 per Pre-Funded Warrant (being the offering price per Share in the offering minus the exercise price). The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, were approximately $105.0 million. The offering closed on May 8, 2024

User Image Pharmer23 Posted - 2 weeks ago

$ADCT 4.39-4.40 is a good place to add shares .

User Image RoacHK1LLaH420 Posted - 2 weeks ago

$ADCT

Analyst Ratings
HC Wainwright & Co. Buy May 7, 24
HC Wainwright & Co. Buy Apr 15, 24
Guggenheim Buy Apr 5, 24
Guggenheim Buy Mar 28, 24
RBC Capital Outperform Mar 14, 24
HC Wainwright & Co. Buy Mar 6, 24
RBC Capital Outperform Feb 26, 24
HC Wainwright & Co. Buy Feb 20, 24
HC Wainwright & Co. Buy Nov 20, 23